LIG1 Loss Reveals Targetable Weakness Against Chemotherapy-Resistant Triple-Negative Breast Cancer
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
Tag: PARP inhibitors
Olaparib Benefits HR-Deficient TNBC and Platinum-Sensitive Ovarian Cancers
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
Optimized Tumor Therapy: Phase I Trial of Gapped Scheduling
In a groundbreaking development that could redefine cancer therapy, researchers have unveiled a novel approach to delivering topoisomerase I (top1) ...
PARP Inhibitors for Recurrent Epithelial Ovarian Cancer
In the dynamic landscape of oncology, researchers continually seek ways to enhance therapeutic strategies for conditions that remain challenging, such ...
UMass Chan Scientists Challenge Traditional Views on the Mechanism of Action of Anticancer Drugs
Recent groundbreaking research conducted by scientists at UMass Chan Medical School has yielded promising insights into the mechanisms underlying the ...
Groundbreaking Real-World Multicenter Study Reveals First Evidence of Olaparib Maintenance Therapy in Newly Diagnosed Homologous Recombination Deficient Positive/BRCA Wild-Type Ovarian Cancer Patients
Ovarian cancer continues to pose significant challenges in gynecological oncology, particularly regarding its treatment and management strategies. The introduction of ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!